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Abstract 
A better understanding of histopathologic and cellular events of COVID-19 
can help us to choose more proper management strategies and treatments. 
There are several ways to cellular and histopathologic evaluations; including, 
tissue sampling from living people as biopsies or dead people as autopsies or 
necropsies. In this study, we tried to evaluate the histopathologic concordance 
between findings of various tissue samplings derived from different sites that 
may work as a mirror of each other, especially mucocutaneous findings which 
may be indicative of similar events of other parts. Based on the main keywords, 
we searched databases of PubMed, Scopus, Google Scholar, Medscape, and 
CEBD coronavirus dermatology resource of Nottingham University and 
included the most relevant and well-designed studies with a higher level of 
pieces of evidence and higher sample size. In this study, selected pathological 
samples from different tissues of patients with COVID-19, including skin and 
mucosa, lungs, gastrointestinal tract, and kidneys were studied and 
summarized. Cellular changes and pathological findings in these patients were 
included by organ and listed by prevalence. Tissue sampling in patients with 
COVID-19 may help understand the pathophysiology of the disease as much 
as possible. Although most of these samples are taken after dying the patients, 
sampling before the more advanced stages of the disease could also show signs 
of tissue involvement before appearing the full systemic symptoms. 
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Introduction 
In the pandemic era of COVID-19, it is important to 
know what happens in the disease course in different 
parts of our body. Involvement of each site could be a 
presenting sign of a new coronavirus with its special 
clinical symptoms, but “how we can access the real 
data in this regard?” 
Tissue sampling evaluations of different organs- 
in living people as biopsies or in dead people as 
autopsies- give access to histopathological events 
during the COVID-19 course. To further improve our 
knowledge about the probable underlying 
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pathophysiology of affected tissues and taking a better 
approach to the treatment, it is needed to understand 
more about histopathological events. In COVID-19, 
skin biopsy of affected patients and primary viral-
related cutaneous manifestation could be an 
appropriate diagnostic method; however, a biopsy of 
internal organs can be done under certain conditions 
but it is very rarely necessary and complex, and 
accompanied by legal ethical issues, while the autopsy 
of internal organs and their histopathological 
examination is much easier under the observance of 
ethical and legal rules that it is quite possible and 
acceptable. 
Based on autopsies, COVID-19 is a systemic 
disease with major cardiovascular and pulmonary 
involvement in a cytokine storm and inflammatory 
setting, associated with a hypercoagulative state and 
susceptibility to microangiopathy and micro/macro 
thrombotic events (1). 
Many efforts have been done to prepare autopsy 
guidelines per detail. Here, we would like to answer 
these questions regarding the COVID-19 course: 
 Is skin biopsy somehow indicative or predictive 
of histopathological events of internal organs so 
to be considered as a substitute for internal organ 
biopsy, necropsy, or autopsy? 
 Is skin biopsy indicative or predictive of 
histopathological events of internal organs? Is 
there histopathological concordance?  
 Can tissue samples and pathological findings 
predict the course of the disease or the occurrence 
of expected clinical manifestations? 
In the setting of pathologic concordance between data 
of various tissue samplings, perhaps the maximum 
biopsy of all available cases with affected skin is a 
good reason to raise our knowledge regarding the 
pathogenesis of the disorder. This is what we tried to 
approach in this comprehensive review. 
We searched databases of PubMed, Scopus, 
Google Scholar, Medscape, and CEBD coronavirus 
dermatology resource of Nottingham University 
(https://www.nottingham.ac.uk/). Our keywords were 
("COVID-19") OR ("severe acute respiratory 
syndrome coronavirus2") AND ("Skin") OR 
("Cutaneous") OR ("Mucosa") OR ("Appendageal") 
OR ("Skin Manifestations") OR ("Dermatology") OR 
("Pathology") OR ("Histology") OR 
("Histopathology") OR ("Histopathologic") OR 
("Histology") OR ("Biopsy") OR ("Autopsy") OR 
("Necropsy"). For writing this comprehensive review, 
we included the most relevant, large (higher sample 
size) and well-designed studies with a higher level of 
evidence. The date of our search was from January 
2020 to June 2020. We searched these databases for 
articles including data of patients who died from 
COVID-19 and being undergone autopsies for 
histopathological evaluation of different vital internal 
organs especially the lung, heart, and liver. In our 
search, we also found a living patient who was assessed 
after lung transplantation for histopathologic changes 
of the extracted lungs. We tried to discuss pathological 
events in different parts of the dead people and 
compare the histopathological findings between 
various organs even mucocutaneous changes. We 
focused on similarities or discrepancies for future 
better judgments about real COVID-19 pathogeneses 
as well as the events that may lead to different organ 
failures or death. 
In this review, we focused on some main 
categories of histopathologic evaluations in COVID-
19 patients; such as mucocutaneous and skin 
appendage histopathologic findings primarily related 
to the virus itself (not to its therapy (adverse cutaneous 
drug reactions)), pulmonary and other internal organ 
tissue sample or biopsy’s histopathologic data and also 
the histopathologic changes and features in various 
sites of autopsies (2-20). The findings of the articles 
are reviewed and the results are presented in the order 
of prevalence in the table below (Table 1).  
Novel coronavirus pneumonia caused by 
SARS-CoV-2 has a worldwide outbreak since it firstly 
occurred in December 2019, Wuhan city, China (21, 
22). It was reported that the virus homology was over 
85% between novel coronavirus pneumonia and severe 
acute respiratory syndrome (SARS). It means that the 
pathological changes of COVID-19 might be similar to 
SARS patients (23). In various tissue samples taken 
from patients with COVID-19, various manifestations 
can be observed depending on the involvement of the 
tissue and clinical symptoms. Using histology in these 
patients may raise our understanding of the 
pathophysiology of the COVID-19 virus. Histological 
studies in these patients mostly include  
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Table 1: COVID-19-induced histopathologic changes in biopsy or autopsy samples of different sites. 
Mucocutaneous 
pathology 
 Sub corneal pustules 
 Spongiosis 
 Papillary dermal edema 
 Perivascular and interstitial inflammatory cells infiltration consist of neutrophil and eosinophil 
 Erythrocyte extravasation 
 Microthrombi /fibrin thrombi 
 Vasculitis (usually necrotizing rather than lymphocytic) 
 Necrosis of the epidermis and dermis 
 Vacuolar degeneration of the basal layer 
 Lichenoid dermatitis 
 Lymphocytic exocytosis to the epidermis and acrosyringia 
 Dyskeratotic cells/ ballooning multinucleated keratinocytes 
 Superficial vascular ectasia 
(Blue: epidermal changes, Green: dermal changes) 
Pulmonary 
pathology 
 Bilateral diffuse alveolar damage (DAD) 
 Proteinaceous exudate 
 Pneumocyte hyperplasia 
 Hyaline membrane formation 
 Syncytial giant cell forms 
 Interstitial fibrosis 
 Vascular lumen stenosis 
 Micro thrombosis formation 
 Alveolar cavity congestion 
 Desquamation and squamous metaplasia in alveolar epithelial cells 
 Inclusion of viral bodies 
Cardiac 
Pathology 
 Mild lymphocytic myocarditis 
 Epicarditis 
 Focal mild fibrosis 
 Mild myocardial hypertrophy 
 Interstitial fibrosis 
Liver Pathology  Periportallymphoplasmacytic infiltration 
 Micro vesicular steatosis 
 Centrilobular sinusoidal dilation 
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 Patchy hepatic necrosis 
 Fibrosis 
 Nuclear glycogenetic in hepatocytes 
 A mild increase in sinusoidal lymphocytes 
 Kupffer cells hyperplasia in few sinusoidal spaces 
Splenic pathology  Diminished white pulp with loss of marginal zones 




 Intramural fibrin deposition 
 Villous stromal-vascular karyorrhexis 
 High-grade chronic villitis with associated avascular villi (obliterative vasculopathy) impaired vascular perfusion 
 Decidualvasculopathy 
 Acute chorioamnionitis and funisitis 
 Meconium-stained amniotic fluid and meconium macrophages  
 Basal chronic villitis 
 Hypercoiled umbilical cord, distal villous immaturity 
 Funisitis 
 Retroplacental hematoma 
 Cord hemangioma 
Renal pathology  Loss of tubular brush border 
 Vacuolar degeneration of the tubular epithelium 
 Dilatation of the tubular lumen with cellular debris 
 Necrosis and detachment of tubular epithelium 
 Hemosiderin granules in tubular epithelium 
 Lymphocytic infiltration subcapsular areas 
 Pseudo crescent appearance in glomerular structure 
 
mucocutaneous, lung, liver, and kidney biopsies. Many 
of these findings have been derived from post-mortem 
sampling. Skin manifestations are also abundant in 
these patients, ranging from viral exanthema to 
vascular manifestations. Skin lesions may occur at any 
stage of the disease from asymptomatic carriers to 
patients admitted to the intensive care unit (ICU). 
Biopsy of these lesions shows different cases that 
correspond to the bed, such as Microthrombi/ fibrin 
thrombi, vasculitis, necrosis of the epidermis and 
dermis, and lichenoid changes. The lungs of the 
patients involved with COVID-19 showed diffuse 
alveolar damage and infiltrating perivascular 
lymphocytes with diffuse congestion and hemorrhagic 
necrosis, proliferative bronchiolitis, and alveolitis with 
pneumocytes proliferation, alveolar epithelial atrophy, 
epithelial desquamation, and squamous metaplasia. 
Similar changes in association with vascular damages 
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include various degrees of inflammatory reactions and 
host immune reaction with variable tissue damages, 
like those seen in skin and lung biopsies, that all may 
be observed in other organs, such as the liver and 
kidneys. Examination of the pathological changes in 
the tissue can predict the manifestations of the disease 
and its course (24). Although most of these tissue 
samples especially from the lungs, liver, or kidneys 
have been prepared since the patient's death, evidence 
of the tissue involvement can be effective in the 
judgment of the disease. 
Mucocutaneous findings are prevalent in 
COVID patients and studies report that about 20% of 
the patients have viral associated dermatologic signs 
that most of them are clinically compatible with 
maculopapular exanthematous or urticarial rash and 
vasculopathy or vasculitic features specially COVID 
Toes (8, 25-28). Histology findings along with viral 
affected pathologic changes and nonspecific 
inflammatory reactions indicate that an important 
group of patients have thrombotic microvascular 
events that are related to certain clinical presentations 
and laboratory hypercoagulative states in some patients 
(12, 29, 30). 
A whole-lung biopsy of a patient who 
developed acute respiratory distress syndrome 
(ARDS) and respiratory failure and underwent lung 
transplantation showed diffuse congestion some 
hemorrhagic necrosis in the tissue. Gross examination 
and serial cuts microscopic histopathologic evaluation 
showed proliferative bronchiolitis and alveolitis with 
Pneumocytes hyperplasia, atrophy of alveolar 
epithelium, epithelial desquamation, and squamous 
metaplasia as well as massive fibrosis with hyaline 
degeneration and various stages of hemorrhagic 
infarction. Massive fibrosis is confirmed by Masson 
staining. The proliferation of thickened wall small 
vessels, luminal stenosis, occlusion, and micro-
thrombosis was another main finding. Monocytes, 
lymphocytes, and plasma cells were infiltrated focally 
to the lung. Infiltrating into the pulmonary interstitium, 
and Immunohistochemistry (IHC) showed CD3, CD4, 
CD8, CD20, CD79a, CD5, CD38, and CD68 positive 
immune cells. Alveolar epithelial cells showed 
atrophy, vacuolar degeneration, proliferation, 
desquamation, and squamous metaplasia, and the 
alveolar cavity was congested and filled by mucus, 
edema fluid, desquamated epithelial cells, and various 
degrees of inflammatory cells.  Multinucleate giant 
cells and intracytoplasmic and intranuclear viral 
inclusion bodies (as viral cytopathic effect) also were 
found. In the COVID-19 course, several representative 
cytokines have been identified including IL-1β, IL-18, 
TNF-α, IL-6, IL-8, and IL-10, which are produced and 
regulated by various immunological cells including 
CD8 and CD4 T cells (31). 
There are many articles regarding autopsies of 
internal organs in COVID-19 patients, especially 
pulmonary, cardiac, and liver samples.  In the lung, 
cytopathic effects usually with no obvious intranuclear 
or intracytoplasmic viral inclusions could also be 
identified as multinucleated syncytial cells with 
atypically enlarged pneumocytes characterized by 
large nuclei, amphophilic granular cytoplasm, and 
prominent nucleoli in intra-alveolar spaces. Fibrotic 
pathogenic events during systemic involvements in 
COVID-19 may be seen, especially in the lung. 
Moreover, important proteinaceous exudates as 
large protein globules, vascular congestion 
accompanied by inflammatory clusters of 
fibrinoid materials, multinucleated giant cells; 
pneumocyte hyperplasia and bilateral diffuse alveolar 
damage (DAD) with cellular fibromyxoid exudates 
also may be observed. Also, desquamated 
pneumocytes and hyaline membrane formation, 
suggesting interstitial mononuclear inflammatory 
infiltrates, were reported in ARDS dominated by 
lymphocytes (32, 33).  
In postmortem needle core biopsies of the lung, 
liver, and heart of four patients who died of COVID-
19 pneumonia, the main histopathologic finding of the 
lung was diffuse alveolar damage (DAD), including 
injury to the alveolar epithelial cells, hyaline 
membrane formation, and pneumocytes type II 
proliferation. Fibrotic degeneration consists of 
fibroblastic proliferation with the extracellular matrix, 
and fibrin cluster formation in airspaces was found. In 
the case of high intra-alveolar neutrophilic infiltration, 
there was bacterial superinfection. Changes in the liver 
and heart are likely secondary or related to the 
underlying diseases or are drug-dependent (especially 
in liver histopathological changes). The liver exhibited 
mild lobular infiltration by small lymphocytes, and 
centrilobular sinusoidal dilation along with patchy 
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necrosis, and the heart showed only focal mild fibrosis 
and mild myocardial hypertrophy (34). 
The most important findings of recent studies 
indicate that the pulmonary small vessel and capillary 
thrombosis and microangiopathy with associated 
hemorrhage can be probably the main cause of the 
death. Severe endothelial injury associated with the 
presence of the intracellular virus and disrupted cell 
membranes and widespread thrombosis with 
microangiopathy could a characteristic feature of the 
lung involvement in COVID-19; so that alveolar-
capillary microthrombi could be 9 times more 
prevalent than that in patients with influenza, and new 
vessel growth (intussusceptive angiogenesis) could be 
2.7 times more prevalent than that in patients with 
influenza. 
DAD including hyaline membrane formation 
could be seen in all patients, even non-intubated ones, 
and it is similar to histopathologic features of 
coronavirus as a severe acute respiratory syndrome 
(SARS). In the heart, individual cell necrosis without 
lymphocytic myocarditis is the most characteristic 
finding. Secondary pulmonary infection by 
microorganisms is of great concern nowadays. Central 
Nervous System did not show any involvement (2, 34, 
35). 
Although viral inclusion bodies in lung 
autopsies are not usual in an autopsy sample from Iran, 
we observed intra-alveolar hemorrhage, moderately 
interstitial inflammation composed of lymphocytes, 
plasma cells and neutrophils, focally necrosis and 
alveolar destruction, intravascular micro-thrombi, and 
large multinucleated pneumocytes with the focal 
presence of intranuclear inclusion like structure 
(maybe due to viral cytopathic effect), desquamation 
of pneumocytes without any evidence of mucus 
plugging within airways. Furthermore, in the liver 
autopsy of another case from Iran, we observed mild 
lobular and portal inflammation dominated by 
lymphocytes, moderate macrovesicular and mild 
microvesicular steatosis with diffuse distribution, 
moderate ballooning degeneration of hepatocytes with 
moderate bile pigment (36).  
Due to the somewhat histopathological 
similarity between the involvements of different 
organs, it is important to know” which organ or organs 
are the main targets of the COVID-19 virus?” 
Since most of the severe complications and 
deaths caused by the virus are due to lung involvement, 
so the lung can be the main target of the virus and other 
organs may be involved secondarily; however, they 
could act as a good predictor of pathologic events in 
the main target organ. Skin is the best example with 
more evident and accessible data among these 
secondary organs (37). 
However, some facts about the actual course of 
COVID-19, the sequels, prognostic factors, treatments, 
and the manner of different parts of the body 
involvement would become clearer in the future, and 
the field of dermatology is not an exception. Some 
concerns are of great importance and need further 
investigation, including The virus-related or drug-
related mucocutaneous signs of COVID-19 (38), 
management of patients with a specific dermatologic 
disorder in the pandemic era (39), or approach to the 
elective therapies especially in the elderly patients (40) 
like cosmetic procedures, non-emergent surgeries, or 
some chronic insignificant medical skin disorders (41), 
and more focus might be given to teledermatology.  
The field of COVID is of interest to the authors 
of this review, and they are interested in COVID-19 
issues in various fields especially COVID-19 and 
dermatology and now they think this topic may a 
valuable concern to discuss (42-45). In the pandemic 
era, there are many concerns about prevention, early 
diagnosis, and treatment of patients with COVID-19 
(46-48) so here we tried to focus on a hot topic that 
may help to increase our knowledge about probable 
pathomechanisms that results to design better 
management protocols.  
 
Conclusion    
This study doubles the importance of tissue sampling. 
First, it helps to know more about the pathophysiology 
of the disease and how different tissues are involved. 
Second, it may be effective in predicting the course of 
the disease and subsequent clinical manifestations. 
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